A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market

Launch of Several Pipeline Oral Products Could Diminish the Market for Injectable Therapies

Regular Price: USD 3,950

Special Price USD 3,555

10% OFF

* Required Fields

Regular Price: USD 3,950

Special Price USD 3,555

PAY BY INVOICE

Be the first to review this product

This market insight provides data for the global multiple sclerosis (MS) market. The analysis looks at MS pharmaceutical pipeline drugs that are currently in the market as well as any drugs that are in Phase III trials and pose a potential threat to competitors. It offers a competitive analysis of these drugs and the forecasted outcome and impact of each of these drugs. Injectable drugs dominate MS drugs currently in the market, but the launch of numerous oral pipeline products can shift this market in favor of oral drugs. The MS market is segmented into relapsing, remitting, secondary progressive, primary progressive, and progressive relapsing MS drugs.

Table of Contents

Executive SummaryKey FindingsRecent Market DevelopmentsRecent Market Developments (continued)Defining Healthcare Trends in the FutureDefining Healthcare Trends in the Future (continued)Companies to WatchMethodology and ScopeMethodology and ScopeIntroductionIntroductionMarket Overview—SegmentationMarket Overview—Segmentation (continued)Market Overview—Segmentation (continued)Market BackgroundPrevalence of MS in Major MarketPrevalence of MS in Major Market (continued)Physician Guidelines to MS TherapyCompetitive LandscapeCompetitive Landscape—Count of Marketed and Pipeline ProductsMS Therapeutics Competitive LandscapeMarketed Product AnalysisMarketed Product Analysis (continued)Pipeline Analysis—Products in Clinical DevelopmentPipeline Analysis—Products in Clinical Development (continued)Pipeline Analysis—Products in Clinical Development (continued)Pipeline Analysis—Products in Clinical Development (continued)Pipeline Analysis—Products in Clinical Development (continued)Pipeline Analysis—Products in Clinical Development (continued)Pipeline Analysis—Products in Clinical Development (continued)Product Launch TimelinePatent Expiration TimelineMarketed Products Clinical Program—AUBAGIO (Teriflunomide)Marketed Products Clinical Program—PlegridyMarketed Products Clinical Program—TysabriMarketed Products Clinical Program—TecfideraPipeline Products Clinical Program—Ocrelizumab, OfatumumabPipeline Products Clinical Program—LemtradaProfiles of Launched and Late Stage Investigational ProductsProduct Dashboard—CopaxoneProduct Dashboard—Avonex (interferon beta-1a)Product Dashboard—Betaseron/Extavia (interferon beta-1b)Product Dashboard—Rebif (interferon beta-1a)Product Dashboard—Tysabri (natalizumab)Product Dashboard—GilenyaProduct Dashboard—Tecfidera (oral Glatiramer Fumarate)Product Dashboard—Aubagio (Teriflunomide)Product Dashboard—Plegridy (BIIB017) (pegylated interferon beta-1a)Product Dashboard—Lemtrada/Campath 1G (Alemtuzumab)Product Dashboard—LaquinimodProduct Dashboard—Zenapax (daclizumab)Product Dashboard—OcrelizumabProduct Dashboard—AB1010 (Masitinib)Product Dashboard—OfatumumabConclusions and RecommendationsConclusions and RecommendationsLegal DisclaimerThe Frost & Sullivan StoryThe Frost & Sullivan StoryValue PropositionGlobal PerspectiveIndustry Convergence360º Research PerspectiveImplementation ExcellenceOur Blue Ocean Strategy




Related Research

Release Date : 20-Sep-17

Region : North America

Release Date : 19-Sep-17

Region : North America

Release Date : 19-Sep-17

Region : North America

Release Date : 19-Sep-17

Region : North America

Release Date : 18-Sep-17

Region : North America

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.